Pilot and feasibility clinical research grants in kidney or urologic diseases (R21).
These grants may be used for plan, pilot, or implement trials that evaluate pharmacologic, dietary, surgical, or behavioral interventions for the prevention or treatment of kidney or urologic disease. Pilot epidemiologic studies are also encouraged. It is anticipated that these grants will in some cases serve as a basis of planning future multicenter research project grant applications (R01), or for cooperative agreement (U01) applications. The purpose of the planning grant is to provide support for investigators at different institutions to meet and design common protocols, entry criteria, data management systems, analysis plans and pilot data for a clinical trial. This would allow investigators to obtain additional expertise during the trial planning phase in areas such as clinical trial design and statistics to develop an R01 grant to support the clinical trial. A pilot clinical grant to plan a large clinical trial (defined as a trial projected to exceed $500,000 direct costs per year) will only be accepted after prior discussions and approval from NIDDK staff. Both new and experienced investigators in relevant fields and disciplines are encouraged to apply for these grants.
It is anticipated that applications submitted in response to this PAR will focus on clinical studies. Basic laboratory research, studies of laboratory animals, or clinical hematology studies are not appropriate for this program announcement. Studies that do not involve human subjects or are nor human studies will not be supported through this funding opportunity. Applications that focus on experimental models of disease are not appropriate for this PAR, but should be submitted to PA-05-103.
Recent estimates of chronic kidney disease (CKD) in the U.S. population, obtained through analysis of the Third National Health and Nutrition Examination Survey (NHANES III), indicate that it is a common medical problem, affecting [greater than or equal to] 10 million people in the U.S. population. Most cases of CKD observed in the United States occur in the setting of diabetes, hypertension, glomerulonephritis, and polycystic kidney disease. The incidence of end-stage renal disease (ESRD) has also been steadily increasing in the adult US population. U.S. Renal Data System (USRDS) data indicate that from 1992-2003 the number of patients with ESRD has increased from 250 to 338 per million population. Although these rates are finally stabilizing, these increases in ESRD rates reflect a marked increase in patient morbidity and mortality related to underlying kidney disease, as well as a significant increase in use of health care resources to provide appropriate care for affected patients. The increasing rate of ESRD has also markedly increased waiting time for cadaveric transplantation such that the rate of kidney transplants per patient year on dialysis has steadily declined over the last decade, from 6.7 per 100 dialysis patients in 1991 to 4.7 in 2003.
Acute kidney injury (AKI; also called acute renal failure) in hospitalized patients is also a significant problem in the United States. Medical management of acute kidney injury has traditionally consisted of supportive care, with renal replacement therapy implemented for the most severe cases. Despite such interventions in acute kidney injury, however, mortality rates in affected patients remain very high (> 50% in some series).
In view of these observations suggesting a high prevalence of CKD, and increasing ESRD and AKI in the U.S. population, NIDDK has sponsored a number of large, multicenter studies of specific kidney disorders. These studies include prospective investigations in chronic kidney disease, dialysis access, polycystic kidney disease, focal and segmental glomerulosclerosis, and acute kidney injury. In planning and performing these studies, however, it has been apparent that the process for identifying appropriate interventions for both single and multicenter trials in kidney disease could be improved. This is particularly evident in the current small number of clinical studies related to kidney disease that could ultimately be expanded to large-scale clinical trials.
Urological diseases and disorders inflict a significant impact on the health care burden of the United States. The NIDDK-funded Urologic Diseases in America Project (UDA) has published data on the four of the most prevalent nonmalignant urological diseases. The data indicate that in 2000, benign prostatic hyperplasia was the primary diagnosis in > 4.4 million office visits, 424,000 emergency room visits and 121,000 hospitalizations with an annual expenditure of > $1.1 billion, besides the increasing cost for outpatient pharmaceuticals. The annual expenditures for urolithiasis totaled more that $2 billion and appears to be increasing with time as the prevalence of stone disease also increases. The health care burden for urinary tract infections, excluding the costs of outpatient pharmaceuticals, exceeded $2.47 billion.
The data for the health care burden of urinary incontinence are more difficult to accurately ascertain because a large percentage of women and men do not report or access care for urinary incontinence. However, the UDA reported that medical expenditures and outpatient visits for urinary incontinence more than doubled from 1992 to 1998. The data for other nonmalignant urological diseases and disorders such as erectile dysfunction, the chronic pelvic pain syndromes such as chronic prostatitis and interstitial cystitis, and the many congenital and acquired pediatric urological disorders are not as rigorous but still demonstrate large and growing health care burden.
The morbidity of many of these nonmalignant urological disorders is compounded by other common comorbid conditions such as diabetes and obesity. Advancement in accurate diagnosis, prevention, and treatment of these diseases is hampered by many factors including a lack of vigorously validated methods to access disease progression, by a lack of insight into the genetics of the disorders, by well-formulated and-tested definitions of the disease and its subcategories, by a lack of rigorous epidemiologic data, and by an imperfect understanding of the mechanism of action of the drugs used to alleviate the symptoms of these diseases and disorders. In addition, often the armamentarium of available diagnostic approaches has not been applied to these diseases.
The goal of this PAR is to provide flexibility for initiating preliminary, short-term studies, thus allowing new ideas to be investigated in a more expeditious manner without stringent requirements for preliminary data. Such support is needed to encourage new and experienced investigators to pursue new approaches, underdeveloped topics, or more risky avenues of research. If successful, these awards should lead to significant scientific advances in the treatment of kidney diseases.
As the kidney and urological diseases occur in a variety of clinical settings, and are associated with a number of comorbid conditions, applications submitted in response to this PAR could address a number of different aspects concerning the prevention, diagnosis, or treatment of patients with kidney and urological diseases.
Relevant topics of study evaluating kidney disease in adults or children could include, but are not limited to 1) diagnosis, epidemiology, disease progression, prevention, preemption, or therapy of patients with, or at risk for, the following conditions: chronic kidney disease, including studies of diabetic nephropathy; hypertensive nephrosclerosis, polycystic kidney disease, or renal allograft dysfunction; glomerular disease, either idiopathic or secondary glomemlar involvement in a systemic process; acute kidney injury, including that observed following renal transplantation; comorbid conditions associated with reduced kidney function; 2) studies assessing dialysis therapy, dialysis access, anemia of renal disease, nutritional, or cardiovascular aspects of ESRD and other comorbid conditions associated with ESRD.
Relevant topics for study of the nonmalignant urological diseases in adults or children could include, but are not limited to 1) diagnostic tools and instruments that can asses the extent and physiological parameters of disease and evaluate disease progression or response to therapy; 2) improved diagnostic criteria for diseases and disease subcategories; 3) accurate epidemiologic data on diseases in various ethnic and racial groups; 4) validated strategies to access early detection of disease, for disease progression and for response to therapy; 5) novel approaches to preventing the onset of disease or preventing the progression of established disease; 6) studies of the effect of the treatment of comorbid disorders on the symptoms, progression, and morbidity of urological diseases.
This funding opportunity will use the NIH Exploratory/Development Research Grant (R21) award mechanism. Information on R21 mechanism is available at http://grants.nih.gov/grants/guide/pa-files/PA03-107.html. These R21 grants will not be renewable; continuation of projects developed under this program will be through the regular research grant (R01) program as new applications. As an applicant, you will be solely responsible for planning, directing, and executing the proposed project.
This funding opportunity uses just-in-time concepts. It also uses the modular as well as the nonmodular budget formats (see http://grants.nih.gov/grants/funding/modular/modular.hrm). Specifically, if you are submitting an application with direct costs in each year of $250,000 or less, use the modular budget format described in the PHS 398 application instructions. Otherwise follow the instructions for nonmodular research grant applications.
The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/ phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance contact Grants Info, 301-435-0714 (telecommunications for the hearing impaired: TTY 301-451-0088) or by e-mail: GrantsInfo@nih.gov.
Applications must be prepared using the most current PHS 398 research grant application instructions and forms. Applications must have a D&B Data Universal Numbering System (DUNS) number as the universal identifier when applying for Federal grants or cooperative agreements. The D&B number can be obtained by calling 866-705-5711 or through the web site at http://www.dnb.com/us/. The D&B number should be entered on line 11 of the face page of the PHS 398 form.
The application submission dates for this PA are available at http://grants.nih.gov/grants/funding/submissionschedule.htm. The complete version of this PA is available at http://grants/nih.gov/grants/guide/pa-files/PAR-06-112
Contacts: Robert A. Star, Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 612, Bethesda, MD 20892-5458 USA, 301-594-7717, fax: 301-480-3510, e-mail: email@example.com; Catherine Meyers, Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Room 725, Bethesda, MD 20892-5458 USA, 301-594-7717, fax: 301-480-3510, e-mail: firstname.lastname@example.org. Reference: PAR-06-112
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Announcements: Fellowships, Grants, & Awards|
|Publication:||Environmental Health Perspectives|
|Date:||May 1, 2006|
|Previous Article:||Thyroid function and perchlorate in drinking water: an evaluation among California newborns, 1998.|
|Next Article:||Autism Centers of Excellence (R01).|